BR112014014868B1 - Composições de hormônio estimulante da tiroide, métodos de produção do mesmo e uso de tais composições - Google Patents

Composições de hormônio estimulante da tiroide, métodos de produção do mesmo e uso de tais composições Download PDF

Info

Publication number
BR112014014868B1
BR112014014868B1 BR112014014868-6A BR112014014868A BR112014014868B1 BR 112014014868 B1 BR112014014868 B1 BR 112014014868B1 BR 112014014868 A BR112014014868 A BR 112014014868A BR 112014014868 B1 BR112014014868 B1 BR 112014014868B1
Authority
BR
Brazil
Prior art keywords
rhtsh
tsh
subunit
peg
amino acid
Prior art date
Application number
BR112014014868-6A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014014868A2 (pt
Inventor
Clark Pan
Sunghae Park
Huawei Qiu
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of BR112014014868A2 publication Critical patent/BR112014014868A2/pt
Publication of BR112014014868B1 publication Critical patent/BR112014014868B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112014014868-6A 2011-12-19 2012-12-04 Composições de hormônio estimulante da tiroide, métodos de produção do mesmo e uso de tais composições BR112014014868B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577412P 2011-12-19 2011-12-19
US61/577,412 2011-12-19
PCT/US2012/067705 WO2013095905A1 (en) 2011-12-19 2012-12-04 Thyroid stimulating hormone compositions

Publications (2)

Publication Number Publication Date
BR112014014868A2 BR112014014868A2 (pt) 2020-10-27
BR112014014868B1 true BR112014014868B1 (pt) 2022-12-27

Family

ID=47520247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014868-6A BR112014014868B1 (pt) 2011-12-19 2012-12-04 Composições de hormônio estimulante da tiroide, métodos de produção do mesmo e uso de tais composições

Country Status (7)

Country Link
US (4) US20140357846A1 (enExample)
EP (1) EP2793948B1 (enExample)
JP (1) JP6255348B2 (enExample)
KR (1) KR102071731B1 (enExample)
CN (1) CN104220097B (enExample)
BR (1) BR112014014868B1 (enExample)
WO (1) WO2013095905A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101687270B1 (ko) 2013-10-29 2016-12-19 한국 한의학 연구원 상륙 추출물 또는 이의 분획물을 함유하는 갑상선 질환의 예방 또는 치료용 조성물
KR101794289B1 (ko) * 2015-11-05 2017-11-06 주식회사 프로젠 재조합 인간 갑상선 자극 호르몬을 포함하는 조성물 및 상기 재조합 인간 갑상선 자극 호르몬의 정제 방법
MA45473A (fr) * 2016-04-04 2019-02-13 Shire Human Genetic Therapies Inhibiteur de c1 estérase conjugué et ses utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0228604A3 (en) 1985-12-11 1988-10-12 Sloan-Kettering Institute For Cancer Research Isolation of a gene encoding human thyrotropin beta subunit
NZ513077A (en) * 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
GB0216780D0 (en) * 2002-07-19 2002-08-28 Bradford Particle Design Ltd Methods of particle formation
KR101145990B1 (ko) * 2002-12-19 2012-08-23 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 시아노비린 변이체-중합체 콘쥬게이트
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
JP2007513191A (ja) * 2003-12-05 2007-05-24 ザイモジェネティクス，インコーポレイティド 甲状腺刺激ホルモンを用いての炎症の処理方法
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
WO2008019036A2 (en) * 2006-08-04 2008-02-14 Pharmathene Inc. Long half-life recombinant butyrylcholinesterase
EP2063909B1 (en) * 2006-09-19 2012-10-24 Genzyme Corporation Formulations for therapeutic administration of thyroid stimulating hormone (TSH)
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
WO2011143274A1 (en) * 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
IT1404011B1 (it) * 2010-12-03 2013-11-08 Uni Degli Studi Magna Graecia Di Catanzaro Nanovettore coniugato con tsh per il trattamento del cancro della tiroide

Also Published As

Publication number Publication date
KR20140103165A (ko) 2014-08-25
CN104220097B (zh) 2019-08-09
US20140357846A1 (en) 2014-12-04
JP2015502363A (ja) 2015-01-22
CN104220097A (zh) 2014-12-17
US20230126645A1 (en) 2023-04-27
JP6255348B2 (ja) 2017-12-27
KR102071731B1 (ko) 2020-01-30
EP2793948A1 (en) 2014-10-29
BR112014014868A2 (pt) 2020-10-27
US20180326082A1 (en) 2018-11-15
HK1198424A1 (en) 2015-04-24
WO2013095905A1 (en) 2013-06-27
US20170065725A1 (en) 2017-03-09
EP2793948B1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
KR101483917B1 (ko) Ｆｖｉｉｉ의 부위 지향 변형
KR101503085B1 (ko) 방출가능한 연결을 갖는 폰 빌레브란드 인자­ 및 인자 ⅷ­폴리머 컨주게이트
US20230126645A1 (en) Thyroid stimulating hormone compositions
US8642545B2 (en) Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof
BRPI0721984B1 (pt) interferon-2b peguilado (ifn-2b), seu método de preparo e de purificação, composição, bem como uso dos mesmos
CN103497247A (zh) 缀合的因子viii分子
JP2015165801A (ja) Ｆｇｆ２１変異体およびその使用
ES2386575T3 (es) Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
BRPI0822530A2 (pt) hormônio do crescimento modificado por polietileno glicol de fita dupla, método de preparação e sua aplicação
CN107849108A (zh) 聚乙二醇化的il‑11的组合物和方法
KR20190031256A (ko) 옥심-함유 결합을 갖는 인자 viii 모이어티의 컨쥬게이트
HK1198424B (en) Thyroid stimulating hormone compositions
CN104447981B (zh) 端羟基聚乙二醇化的人胰岛素及其类似物的偶联物
WO2023227015A1 (zh) 具有延长的半衰期的fviii融合蛋白缀合物及其应用
JP6367952B2 (ja) エリスロポエチンおよび分枝ポリマー構造を含む複合体
BRPI0720661B1 (pt) Conjugados do polímero-fator de von willebrand e polímero-do fator viii tendo uma ligação liberável, método e composição relacionados

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.